Tradestie Institutional Equity Comparison Engine
ZBIO vs VTYX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VTYX Overall Edge
VTYX Captures Institutional Edge (2โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ventyx Biosciences, Inc. Common Stock (VTYX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus VTYX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZBIO sits in CONSOLIDATION (12th %ile IV; Dealer Gamma Walls on Pro) against VTYX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ZBIO N/M vs VTYX N/M Fwd P/E
Growth & Margin Winner
VTYX
Op Margin -2747.5% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
VTYX
1Y -22.5% vs +786.1% ยท 52W Pos 46% vs 55%
Options & Structure Winner
Tie
CONSOLIDATION (12th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
ZBIO
NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.64
-1.32% 1D
Market Cap
$1.9B
1M Return
+11.27%
1Y Return
-22.49%
Forward P/E
N/M
Unified AI Score
49.4 / 100
HOLD
Tech 44.0
Fund 53.0
Flow 69.0
Mom 50.0
VTYX
NASDAQ
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap
$1.0B
1M Return
+0.36%
1Y Return
+786.08%
Forward P/E
N/M
Unified AI Score
50.4 / 100
HOLD
Tech 40.0
Fund 50.0
Flow 69.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ZBIO -22.49%
VTYX +786.08%
Spread: +75.99 pp (VTYX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ZBIO TTM Op. Margin: -2747.5%
VTYX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs VTYX. Trailing 12-month operating profitability (ZBIO -2747.5% vs VTYX 0.0%) and valuation multiples (ZBIO N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZBIO | VTYX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $1.0B | Larger Scale | ZBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | VTYX |
| Operating Margin (TTM) Profitability | -2747.5% | 0.0% | Higher Margin | VTYX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -265.1% | -45.4% | Higher ROE | VTYX |
| 52-Week Range Position Momentum | 46% ($14โ$45) | 55% ($1โ$25) | Stronger Trend | VTYX |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 59% Vol | 2.07ฮฒ ยท 2% Vol | Lower Realized Risk | VTYX |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 50.4 / 100 (HOLD) | Higher Composite | VTYX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ZBIO vs VTYX Buy Guide
ZBIO
CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
VTYX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ZBIO nor VTYX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.